3SBio Inc. (FRA:83B)

Market Cap	7.55B
Revenue (ttm)	1.08B
Net Income (ttm)	280.34M
Shares Out	n/a
EPS (ttm)	0.11
PE Ratio	26.93
Forward PE	10.48
Dividend	0.03 (0.89%)
Ex-Dividend Date	Jul 21, 2025

Volume	n/a
Average Volume	2,931
Open	3.120
Previous Close	3.060
Day's Range	3.080 - 3.120
52-Week Range	0.625 - 3.880
Beta	n/a
RSI	47.40
Earnings Date	Nov 11, 2025

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC ex...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 5,577
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 83B

Financial Performance

In 2024, 3SBio's revenue was 9.11 billion, an increase of 16.53% compared to the previous year's 7.82 billion. Earnings were 2.09 billion, an increase of 34.93%.

Financial numbers in CNY